Lung disease
A selection of insight articles on the topic of lung disease biomarkers:
Can KL-6 be a specific marker of alveolar damage for COVID-19 patients?
There are many reference centers across Europe that have included KL-6 as one of the biomarkers within the COVID-19 protocol to strengthen the battery...
Apr 30, 2020
From Classification to disease activity
While IPF is the classic fibrosing ILD, clinical data suggest that there is a larger group of patients with differing clinical ILD diagnoses who...
Dec 17, 2019
Recent research has shown that serum and bronchoalveolar lavage fluid level of KL-6 has an important value in the diagnosis, treatment assessment and...
Dec 2, 2019
Use of serum biomarkers in progressive fibrosing ILDs
Based on the results from a number of reports investigating KL-6/MUC1, the serum levels of KL-6/MUC1 are useful for 1) detecting the presence of...
Nov 18, 2019
ILD diagnosis – current professional practice
Accurate diagnosis of IPF is critical, as other forms of ILD that have similar clinical presentations to IPF require different treatment strategies.
Nov 5, 2019
KL-6 in Lung Diseases: Current classification of interstitial lung diseases
Interstitial lung diseases (ILDs) represent a large, heterogeneous group of more than 200 different entities, most of which are classified as rare...
Oct 24, 2019
Mesothelin, the novel, non-invasive in vitro biomarker to aid in the diagnosis of Mesothelioma
Mesothelioma is a rare form of cancer that is linked to exposure to asbestos. Although malignant mesothelioma remains a relatively uncommon malignancy...
Jun 6, 2019
